Summary
Currently available pre-birth surgical treatments for Spina Bifida Aperta (SBA) still do not provide a complete recovery in babies and would potentially benefit from a tissue engineering approach, indeed the first clinical trial using stem cells for SBA has recently started, however this is performed via an open-uterus approach. This made me wonder, what if we can develop an innovative system to deliver via fetoscopy a bioprinted tissue engineering costructfor SBA repair? Such an approach would promote tissue regeneration and ease the surgery.
In 3D.FETOPRINT I will develop a system for the in-situ fetoscopic bioprinting of a gel composed of extracellular matrix (ECM) proteins and amniotic fluid stem cells (AFSCs) to close the defect of spina bifida aperta (SBA) in a large animal model.
The project will be divided into three work packages. First work package will address the development and testing of the gel, by studying the interaction between fetal ECM proteins and AFSCs, to define a gel formulation that could be bioprinted in-utero. Second work package will focus on the design and development of an innovative fetoscopic bioprinting device capable of bioprinting a gel patch on the fetus. Last work package will finally validate the innovative approach. We will first validate through in-vitro testing using a laparoscopic simulator, then we will perform a sheep spina bifida aperta model where the innovative fetoscopic 3D bioprinting system will be vaildated.
We will leverage my expertise in biomaterials, cells and tissue engineering device design to carry out this project that will deliver a revolutionary system that will open up the possibility to bioprint tissue engineered constructs on the fetus.
In 3D.FETOPRINT I will develop a system for the in-situ fetoscopic bioprinting of a gel composed of extracellular matrix (ECM) proteins and amniotic fluid stem cells (AFSCs) to close the defect of spina bifida aperta (SBA) in a large animal model.
The project will be divided into three work packages. First work package will address the development and testing of the gel, by studying the interaction between fetal ECM proteins and AFSCs, to define a gel formulation that could be bioprinted in-utero. Second work package will focus on the design and development of an innovative fetoscopic bioprinting device capable of bioprinting a gel patch on the fetus. Last work package will finally validate the innovative approach. We will first validate through in-vitro testing using a laparoscopic simulator, then we will perform a sheep spina bifida aperta model where the innovative fetoscopic 3D bioprinting system will be vaildated.
We will leverage my expertise in biomaterials, cells and tissue engineering device design to carry out this project that will deliver a revolutionary system that will open up the possibility to bioprint tissue engineered constructs on the fetus.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101126209 |
| Start date: | 01-06-2024 |
| End date: | 31-05-2029 |
| Total budget - Public funding: | 1 972 500,00 Euro - 1 972 500,00 Euro |
Cordis data
Original description
Currently available pre-birth surgical treatments for Spina Bifida Aperta (SBA) still do not provide a complete recovery in babies and would potentially benefit from a tissue engineering approach, indeed the first clinical trial using stem cells for SBA has recently started, however this is performed via an open-uterus approach. This made me wonder, what if we can develop an innovative system to deliver via fetoscopy a bioprinted tissue engineering costructfor SBA repair? Such an approach would promote tissue regeneration and ease the surgery.In 3D.FETOPRINT I will develop a system for the in-situ fetoscopic bioprinting of a gel composed of extracellular matrix (ECM) proteins and amniotic fluid stem cells (AFSCs) to close the defect of spina bifida aperta (SBA) in a large animal model.
The project will be divided into three work packages. First work package will address the development and testing of the gel, by studying the interaction between fetal ECM proteins and AFSCs, to define a gel formulation that could be bioprinted in-utero. Second work package will focus on the design and development of an innovative fetoscopic bioprinting device capable of bioprinting a gel patch on the fetus. Last work package will finally validate the innovative approach. We will first validate through in-vitro testing using a laparoscopic simulator, then we will perform a sheep spina bifida aperta model where the innovative fetoscopic 3D bioprinting system will be vaildated.
We will leverage my expertise in biomaterials, cells and tissue engineering device design to carry out this project that will deliver a revolutionary system that will open up the possibility to bioprint tissue engineered constructs on the fetus.
Status
SIGNEDCall topic
ERC-2023-COGUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
Search
